search
Back to results

SAMe Trial for Patients With Alcoholic Cirrhosis

Primary Purpose

Alcoholic Cirrhosis

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Placebo
SAMe 400 mg tablet
Sponsored by
Indiana University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Alcoholic Cirrhosis focused on measuring Child Class A or B

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria for patients with alcoholic cirrhosis

  1. Patients must have had alcohol consumption averaging at least 80 grams per day (for men) or 50 grams per day (for women), for at least 10 years. These criteria are based on epidemiological evidence of the alcohol-cirrhosis relationship. The cutoff was set at a relatively high level so as to minimize the chance that cirrhosis was caused by factors other than alcohol
  2. Evidence of cirrhosis as per clinical signs and/or noninvasive transient elastography (Fibroscan®), computed tomography, magnetic resonance imaging including MRI elastography compatible with cirrhosis and/or histopathology by biopsy and
  3. subjects with clinical presentation either in Child Class A or B at the time of enrollment

Inclusion criteria for healthy control :

  1. individuals 18 to 70 years old
  2. able to provide informed consent
  3. subjects do not consume any alcohol or those who drink < 50 grams per day on average in women and < 80 grams per day on average in men and do not consume any alcohol within 3 months before the study and
  4. subjects are healthy without underlying acute or chronic medical conditions.

Exclusion criteria for patients with alcoholic cirrhosis

  1. Active infection as evidenced by positive urine culture, blood culture, or pneumonia,
  2. Serum creatinine >1.5 mg/dl
  3. Known co-existing infection with hepatitis C, hepatitis B, or HIV
  4. Significant systemic or major illness including chronic obstructive pulmonary disease, congestive heart failure, and renal failure that in the opinion of the Investigator would preclude the patient from participating in and completing the study
  5. Gastrointestinal bleeding within the prior 28 days3
  6. Participation in another investigational drug, biologic, or medical device trial within 30 days prior to screening
  7. Women who are pregnant, may become pregnant, or nursing
  8. Presence of any other disease or condition that is interfering with the absorption, distribution, metabolism, or excretion of SAMe such as those with gastric bypass surgery
  9. Subjects with history of/diagnosis of hepatocellular carcinoma
  10. Members from the same family of study participant. This is based on the recent paper on the non-random sampling in randomized controlled trials4. We acknowledge that if we assign family members to identical treatment, randomization would not be totally correct; but if properly randomized, there is a chance that the members of the family might mix the pills. To avoid this issue and maintain the integrity of randomized blinded fashion, we will not include members from the same family into the study
  11. Subjects with psychiatric illnesses such as bipolar disorders as SAMe may interfere with the levels of anti-psychotic drugs and
  12. Systemic antibiotic use or use of rifaximin for 10 days or more in last 2 months before the enrollment.

Exclusion criteria for all healthy control participants:

  1. individuals under the age of 18 or over the age of 70
  2. not able to provide informed consent
  3. subjects who consume any alcohol or those who drink > 50 grams per day on average in women and > 80 grams per day on average in men and consume any alcohol within 3 months before the study and
  4. subjects that are unhealthy with underlying acute or chronic medical conditions.

Sites / Locations

  • Cedars-Sinai Medical CenterRecruiting
  • Indiana University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

No Intervention

Arm Label

Placebo

1,200 mg SAMe

Non-drinking Controls

Arm Description

Alcoholic Cirrhosis on placebo

SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months

Non-drinking healthy controls

Outcomes

Primary Outcome Measures

SAMe supplement's effect on all-cause mortality
The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.

Secondary Outcome Measures

SAMe supplement's effect on intestinal permeability function, as defined by serum lipopolysaccharides (LPS)
The function of intestinal permeability will be evaluated by testing serum lipopolysaccharides (LPS) in patients who receive SAMe compared to those who receive placebo. Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide that are bacterial toxins.
SAMe supplement's effect on cellular oxidative stress and/or endoplasmic reticulum (ER) stress, as defined by mitochondrial DNA
Cellular oxidative stress and/or endoplasmic reticulum (ER) stress will be evaluated by measuring the levels of mitochondrial DNA in the blood of patients who receive SAMe compared to those who receive placebo.
SAMe supplement's effect on liver deuteriation
determining Proportion of subjects undergoing liver transplantation in patients who receive SAMe compared to those who receive placebo
SAMe supplement's effect on liver developing cancer
Proportion of subjects developing new onset hepatocellular carcinoma in patients who receive SAMe compared to those who receive placebo
SAMe supplement's effect on infections of the liver
Proportion of subjects with infection/sepsis (other than SBP) in patients who receive SAMe compared to those who receive placebo
SAMe supplement's effect on other parts of the body
capture safety-related endpoints by determining proportion of patients with nausea and emesis, proportion of subjects with unexplained diarrhea in patients receive SAMe compared to those who receive placebo.
SAMe supplement's effects on intestinal permeability function, as defined by soluble(s) CD14
The function of intestinal permeability will be evaluated by testing soluble(s) CD14 in patients who receive SAMe compared to those who receive placebo. sCD14 either appears after shedding of mCD14 (48 kDa) or is directly secreted from intracellular vesicles (56 kDa).
SAMe supplement's effects on intestinal permeability function, as defined by soluble(s) CD163
The function of intestinal permeability will be evaluated by testing soluble(s) CD163 in patients who receive SAMe compared to those who receive placebo. CD163 is an endocytic receptor for haptoglobin-hemoglobin complexes and is expressed solely on macrophages and monocytes. As a result of ectodomain shedding, the extracellular portion of CD163 circulates in blood as a soluble protein (sCD163).
SAMe supplement's effects on cellular oxidative stress and/or endoplasmic reticulum (ER) stress, as defined by cytochrome P450 2E1 levels
Levels of cellular oxidative stress and/or endoplasmic reticulum (ER) stress will be evaluated by measuring the levels of cytochrome P450 2E1 (CYP2E1) enriched microparticles in patients who receive SAMe compared to those who receive placebo.CYP2E1 is a member of the cytochrome P450 mixed-function oxidase system, which is involved in the metabolism of xenobiotics in the body.

Full Information

First Posted
January 22, 2020
Last Updated
October 2, 2023
Sponsor
Indiana University
Collaborators
Cedars-Sinai Medical Center, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
search

1. Study Identification

Unique Protocol Identification Number
NCT04250259
Brief Title
SAMe Trial for Patients With Alcoholic Cirrhosis
Official Title
A Multi-center, Randomized, Placebo-controlled Trial of S-Adenosylmethionine (SAMe) in Patients With Alcoholic Cirrhosis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 22, 2020 (Actual)
Primary Completion Date
September 1, 2025 (Anticipated)
Study Completion Date
September 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indiana University
Collaborators
Cedars-Sinai Medical Center, National Institute on Alcohol Abuse and Alcoholism (NIAAA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The proposed of this randomized, double blinded, placebo-controlled study is to assess the effect of SAMe compared to placebo in patients with alcoholic cirrhosis Child Class A and B. The primary objective of the study is to test relationship between SAMe (S-adenosylmethionine) supplement on liver function. The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcoholic Cirrhosis
Keywords
Child Class A or B

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
196 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Alcoholic Cirrhosis on placebo
Arm Title
1,200 mg SAMe
Arm Type
Experimental
Arm Description
SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
Arm Title
Non-drinking Controls
Arm Type
No Intervention
Arm Description
Non-drinking healthy controls
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
Intervention Type
Drug
Intervention Name(s)
SAMe 400 mg tablet
Intervention Description
SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
Primary Outcome Measure Information:
Title
SAMe supplement's effect on all-cause mortality
Description
The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.
Time Frame
Baseline to end of 24 months
Secondary Outcome Measure Information:
Title
SAMe supplement's effect on intestinal permeability function, as defined by serum lipopolysaccharides (LPS)
Description
The function of intestinal permeability will be evaluated by testing serum lipopolysaccharides (LPS) in patients who receive SAMe compared to those who receive placebo. Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide that are bacterial toxins.
Time Frame
baseline to end of 24 months
Title
SAMe supplement's effect on cellular oxidative stress and/or endoplasmic reticulum (ER) stress, as defined by mitochondrial DNA
Description
Cellular oxidative stress and/or endoplasmic reticulum (ER) stress will be evaluated by measuring the levels of mitochondrial DNA in the blood of patients who receive SAMe compared to those who receive placebo.
Time Frame
baseline to 24 months
Title
SAMe supplement's effect on liver deuteriation
Description
determining Proportion of subjects undergoing liver transplantation in patients who receive SAMe compared to those who receive placebo
Time Frame
baseline to 24 months
Title
SAMe supplement's effect on liver developing cancer
Description
Proportion of subjects developing new onset hepatocellular carcinoma in patients who receive SAMe compared to those who receive placebo
Time Frame
baseline to 24 months
Title
SAMe supplement's effect on infections of the liver
Description
Proportion of subjects with infection/sepsis (other than SBP) in patients who receive SAMe compared to those who receive placebo
Time Frame
baseline to 24 months
Title
SAMe supplement's effect on other parts of the body
Description
capture safety-related endpoints by determining proportion of patients with nausea and emesis, proportion of subjects with unexplained diarrhea in patients receive SAMe compared to those who receive placebo.
Time Frame
baseline to 24 months
Title
SAMe supplement's effects on intestinal permeability function, as defined by soluble(s) CD14
Description
The function of intestinal permeability will be evaluated by testing soluble(s) CD14 in patients who receive SAMe compared to those who receive placebo. sCD14 either appears after shedding of mCD14 (48 kDa) or is directly secreted from intracellular vesicles (56 kDa).
Time Frame
baseline to 24 months
Title
SAMe supplement's effects on intestinal permeability function, as defined by soluble(s) CD163
Description
The function of intestinal permeability will be evaluated by testing soluble(s) CD163 in patients who receive SAMe compared to those who receive placebo. CD163 is an endocytic receptor for haptoglobin-hemoglobin complexes and is expressed solely on macrophages and monocytes. As a result of ectodomain shedding, the extracellular portion of CD163 circulates in blood as a soluble protein (sCD163).
Time Frame
baseline to 24 months
Title
SAMe supplement's effects on cellular oxidative stress and/or endoplasmic reticulum (ER) stress, as defined by cytochrome P450 2E1 levels
Description
Levels of cellular oxidative stress and/or endoplasmic reticulum (ER) stress will be evaluated by measuring the levels of cytochrome P450 2E1 (CYP2E1) enriched microparticles in patients who receive SAMe compared to those who receive placebo.CYP2E1 is a member of the cytochrome P450 mixed-function oxidase system, which is involved in the metabolism of xenobiotics in the body.
Time Frame
baseline to 24 months
Other Pre-specified Outcome Measures:
Title
Exploratory outcome - identify who will improve their liver functions by taking the SAMe supplement amongst those that have been diagnosed with alcoholic cirrhosis (Child-Pugh score of A or B).
Description
The metabolic profiling of the serum and urine will be collected by those in the study who received the SAMe supplement and will be used as the surrogates for this prediction.
Time Frame
baseline to 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria for patients with alcoholic cirrhosis Evidence of cirrhosis as per clinical signs and/or noninvasive transient elastography (Fibroscan®), computed tomography, magnetic resonance imaging including MRI elastography compatible with cirrhosis and/or histopathology by biopsy and subjects with clinical presentation either in Child Class A or B at the time of enrollment individuals 18 to 70 years old and may or may not consume alcohol during study. Inclusion criteria for healthy control : ) individuals 18 to 70 years old (2) able to provide informed consent (3) subjects do not consume any alcohol or those who drink < 50 grams per day on average in women and < 80 grams per day on average in men (4) subjects are healthy without underlying acute or chronic medical conditions. Exclusion criteria for patients with alcoholic cirrhosis Active infection as evidenced by positive urine culture, blood culture, or pneumonia, Known co-existing infection with hepatitis C, hepatitis B, or HIV Significant systemic or major illness including chronic obstructive pulmonary disease, congestive heart failure, and renal failure that in the opinion of the Investigator would preclude the patient from participating in and completing the study Gastrointestinal bleeding within the prior 28 days3 Participation in another investigational drug, biologic, or medical device trial within 30 days prior to screening Women who are pregnant, may become pregnant, or nursing Presence of any other disease or condition that is interfering with the absorption, distribution, metabolism, or excretion of SAMe such as those with gastric bypass surgery Subjects with history of/diagnosis of hepatocellular carcinoma Members from the same family of study participant. This is based on the recent paper on the non-random sampling in randomized controlled trials4. We acknowledge that if we assign family members to identical treatment, randomization would not be totally correct; but if properly randomized, there is a chance that the members of the family might mix the pills. To avoid this issue and maintain the integrity of randomized blinded fashion, we will not include members from the same family into the study Subjects with psychiatric illnesses such as bipolar disorders as SAMe may interfere with the levels of anti-psychotic drugs and Subjects who are immunocompromised Exclusion criteria for all healthy control participants: subjects with an active and serious medical disease subjects with an infectious disease consume any alcohol within 3 months before the study subjects with localized or systemic infection
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kristina Chandler, BS
Phone
(317) 988-4733
Email
krimhick@iu.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Maggie Hesler, BS
Phone
(317) 988-4545
Email
mshesler@iu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Suthat Liangpunsakul, MD
Organizational Affiliation
Indiana University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cedars-Sinai Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brandon Love
Phone
310-423-9917
Email
brandon.love@cshs.org
First Name & Middle Initial & Last Name & Degree
Shelly Lu, MD
Facility Name
Indiana University Hospital
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kristina Chandler, BS
Phone
317-988-4733
Email
krimhick@iu.edu
First Name & Middle Initial & Last Name & Degree
Maggie Hesler, BS
Phone
3179884545
Email
mshesler@iu.edu
First Name & Middle Initial & Last Name & Degree
Suthat Liangpunsakul, MD

12. IPD Sharing Statement

Learn more about this trial

SAMe Trial for Patients With Alcoholic Cirrhosis

We'll reach out to this number within 24 hrs